Skip to Content

Cytarabine Injection

Last Updated: April 16, 2018
Status: Current

Abciximab Injection

Products Affected - Description
    • Reopro intravenous injection, Janssen, 2 mg/mL, 5 mL vial, 1 count, NDC 57894-0200-01
Reason for the Shortage
    • Janssen has Reopro on shortage due to a production interruption at their third party manufacturing site. The contract manufacturer cannot guarantee supply continuity in 2018 and beyond.
    • There are no other suppliers of abciximab.

Estimated Resupply Dates

    • Janssen has Reopro on long-term back order and the company cannot estimate a release date.


Created April 16, 2018 by Megan Dryer, PharmD. Copyright 2018, Drug Information Service, University of Utah, Salt Lake City, UT.